JP2016128399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128399A5 JP2016128399A5 JP2015118495A JP2015118495A JP2016128399A5 JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5 JP 2015118495 A JP2015118495 A JP 2015118495A JP 2015118495 A JP2015118495 A JP 2015118495A JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- lipophilic
- amino acids
- group
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/075722 WO2016091487A1 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| PL15793746T PL3230318T3 (pl) | 2014-12-11 | 2015-11-04 | Kombinacje inhibitora immunologicznego punktu kontrolnego |
| DK15793746.7T DK3230318T3 (da) | 2014-12-11 | 2015-11-04 | Immune checkpoint-inhibitor-kombinationer |
| US15/534,800 US11083774B2 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| HUE15793746A HUE051268T2 (hu) | 2014-12-11 | 2015-11-04 | Immunellenõrzõpont-gátló kombinációk |
| LTEP15793746.7T LT3230318T (lt) | 2014-12-11 | 2015-11-04 | Imuninės kontrolės taško inhibitorių kombinacijos |
| PT157937467T PT3230318T (pt) | 2014-12-11 | 2015-11-04 | Combinações de inibidores de pontos de controlo imunitários |
| AU2015359881A AU2015359881B2 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| EP15793746.7A EP3230318B1 (en) | 2014-12-11 | 2015-11-04 | Immune checkpoint inhibitor combinations |
| ES15793746T ES2819282T3 (es) | 2014-12-11 | 2015-11-04 | Combinaciones de inhibidores de puntos de control inmunitarios |
| AU2019203199A AU2019203199B2 (en) | 2014-12-11 | 2019-05-07 | Immune checkpoint inhibitor combinations |
| AU2021204356A AU2021204356B2 (en) | 2014-12-11 | 2021-06-25 | Immune checkpoint inhibitor combinations |
| US17/366,463 US20230201305A9 (en) | 2014-12-11 | 2021-07-02 | Immune checkpoint inhibitor combinations |
| US18/598,719 US12239686B2 (en) | 2014-12-11 | 2024-03-07 | Immune checkpoint inhibitor combinations |
| US19/022,157 US20250332217A1 (en) | 2014-12-11 | 2025-01-15 | Immune checkpoint inhibitor combinations |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1422084.2 | 2014-12-11 | ||
| GB201422084 | 2014-12-11 | ||
| GB1506127.8 | 2015-04-10 | ||
| GBGB1506127.8A GB201506127D0 (en) | 2015-04-10 | 2015-04-10 | Immune checkpoint inhibitor combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128399A JP2016128399A (ja) | 2016-07-14 |
| JP2016128399A5 true JP2016128399A5 (enExample) | 2018-05-10 |
| JP6767096B2 JP6767096B2 (ja) | 2020-10-14 |
Family
ID=56384106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015118495A Active JP6767096B2 (ja) | 2014-12-11 | 2015-06-11 | 免疫チェックポイント阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11083774B2 (enExample) |
| EP (1) | EP3230318B1 (enExample) |
| JP (1) | JP6767096B2 (enExample) |
| AU (3) | AU2015359881B2 (enExample) |
| DK (1) | DK3230318T3 (enExample) |
| ES (1) | ES2819282T3 (enExample) |
| HU (1) | HUE051268T2 (enExample) |
| LT (1) | LT3230318T (enExample) |
| PL (1) | PL3230318T3 (enExample) |
| PT (1) | PT3230318T (enExample) |
| WO (1) | WO2016091487A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| US11666646B2 (en) | 2016-12-26 | 2023-06-06 | National University Corporation Kobe University | Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor |
| WO2018188761A1 (en) * | 2017-04-13 | 2018-10-18 | Lytix Biopharma As | Method of reducing population size of tregs and/or mdscs |
| WO2019240218A1 (ja) | 2018-06-14 | 2019-12-19 | 株式会社明治 | 免疫チェックポイント阻害療法を促進するための組成物 |
| CA3139242A1 (en) * | 2019-06-20 | 2020-12-24 | Viengkham Malathong | Compounds for treatment of pd-l1 diseases |
| CN110317245B (zh) * | 2019-08-02 | 2021-04-09 | 郑州大学 | Lag-3蛋白亲和环肽及其应用 |
| EP4045037A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | HETEROARYL-BIPHENYL AMINE FOR THE TREATMENT OF PD-L1 DISEASE |
| US20230037966A1 (en) * | 2020-01-07 | 2023-02-09 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
| WO2024133588A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Compositions comprising an oncolytic peptide and chitosan |
| WO2024133580A1 (en) | 2022-12-20 | 2024-06-27 | Lytix Biopharma As | Medical products containing an aqueous formulation of a peptide |
| CN117402828A (zh) * | 2023-04-13 | 2024-01-16 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种人肺癌脑转移瘤细胞系及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| ES2311303T3 (es) | 1998-05-04 | 2009-02-01 | Thomas Jefferson University | Uso de celulas tumorales sometidas a hapteno y extractos de las mismas. |
| GB0605685D0 (en) | 2006-03-21 | 2006-05-03 | Lytix Biopharma As | Inhibition of tumour growth |
| AU2003281200A1 (en) * | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| CA2775761C (en) | 2009-09-30 | 2018-08-28 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| US9410206B2 (en) * | 2011-11-30 | 2016-08-09 | John Wayne Cancer Institute | Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer |
| US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| EA201691683A1 (ru) * | 2014-02-21 | 2017-04-28 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме |
| EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| JP6813258B2 (ja) * | 2014-12-11 | 2021-01-13 | リティックス バイオファーマ エイエス | 化学療法の組み合わせ |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
-
2015
- 2015-06-11 JP JP2015118495A patent/JP6767096B2/ja active Active
- 2015-11-04 LT LTEP15793746.7T patent/LT3230318T/lt unknown
- 2015-11-04 WO PCT/EP2015/075722 patent/WO2016091487A1/en not_active Ceased
- 2015-11-04 PT PT157937467T patent/PT3230318T/pt unknown
- 2015-11-04 DK DK15793746.7T patent/DK3230318T3/da active
- 2015-11-04 HU HUE15793746A patent/HUE051268T2/hu unknown
- 2015-11-04 EP EP15793746.7A patent/EP3230318B1/en active Active
- 2015-11-04 PL PL15793746T patent/PL3230318T3/pl unknown
- 2015-11-04 ES ES15793746T patent/ES2819282T3/es active Active
- 2015-11-04 US US15/534,800 patent/US11083774B2/en active Active
- 2015-11-04 AU AU2015359881A patent/AU2015359881B2/en active Active
-
2019
- 2019-05-07 AU AU2019203199A patent/AU2019203199B2/en active Active
-
2021
- 2021-06-25 AU AU2021204356A patent/AU2021204356B2/en active Active
- 2021-07-02 US US17/366,463 patent/US20230201305A9/en not_active Abandoned
-
2024
- 2024-03-07 US US18/598,719 patent/US12239686B2/en active Active
-
2025
- 2025-01-15 US US19/022,157 patent/US20250332217A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016128399A5 (enExample) | ||
| CN104853776B (zh) | 免疫应答的增强 | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| JP2018501197A5 (enExample) | ||
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| MX2018001193A (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2018530554A5 (enExample) | ||
| JP2016527286A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| JP2018522045A5 (enExample) | ||
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| AU2021203564B2 (en) | Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors | |
| JP2017503014A5 (enExample) | ||
| BR112018001534A2 (pt) | inibidor de isocitrato desidrogenase idh1 r132h mutante | |
| EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| RU2011123700A (ru) | Нонапептид с противоопухолевой активностью | |
| JP2018519324A5 (enExample) | ||
| JP2024133495A (ja) | 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| JP2016515550A5 (enExample) | ||
| EP3209328B1 (en) | Inhibitors of lactate transporters for use in the treatment of inflammatory diseases | |
| EA201101305A1 (ru) | Лечение рака поджелудочной железы |